
Chong Kun Dang Pharmaceutical Corp
KRX:185750

Operating Margin
Chong Kun Dang Pharmaceutical Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
KR |
![]() |
Chong Kun Dang Pharmaceutical Corp
KRX:185750
|
1.1T KRW |
5%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
677.8B USD |
40%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
367.1B USD |
26%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
48%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.2B CHF |
33%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
182.2B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.9B GBP |
24%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
195.9B USD |
34%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
117.1B EUR |
22%
|
Chong Kun Dang Pharmaceutical Corp
Glance View
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-12-06. The firm is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The firm sells products in domestic and overseas markets.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Chong Kun Dang Pharmaceutical Corp's most recent financial statements, the company has Operating Margin of 5%.